Tuesday, May 17, 2022 7:47:55 AM
With Moderna's focus on respiratory diseases, the Company has invested in designing mRNA delivery systems tailored to targeting pulmonary disease. For pulmonary applications, delivery of mRNA medicines directly to the lungs by inhalation is the preferred method of administration in order to maximize the concentration of the medicine locally in the lung. Moderna researchers have developed a new LNP formulation that addresses many of the challenges associated with lung delivery of mRNA. This pulmonary LNP formulation is delivered by inhalation, uses multiple lipids, and is able to target specific areas of the lung. Moderna's optimization of pulmonary delivery of mRNA provides opportunities to address a range of unmet medical needs.
Moderna is collaborating with Vertex to deliver mRNA directly to the lungs via aerosolization to enable production of a functional cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein. CFTR is an important target for treatment because it is a defect in the CFTR gene that leads to buildup of thick mucus in the airways, chronic lung infections, inflammation and eventual respiratory failure. To date, the companies have completed IND studies that are supportive of advancing to clinical development. Vertex expects to submit an IND for this program in the second half of this year. In a second collaboration, the companies are collaborating to develop a portfolio of mRNA CF treatments, through the discovery and development of novel LNPs and mRNAs for the delivery of gene-editing therapies for the treatment of CF.
BIG COMPANY "The future is now, my friend"
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Advancements-in-mRNA-Platform-Science-for-Application-Across-Multiple-Diseases-at-Science-and-Technology-Day/default.aspx
Recent MRNA News
- Moderna, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/23/2024 09:45:00 AM
- The Gross Law Firm Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/16/2024 09:45:00 AM
- OpenAI Unveils Strawberry AI Model Series; Boeing Stock Falls 4% Amid Strike; HR Surges 20% on Growth Forecast • IH Market News • 09/13/2024 10:12:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 10:03:14 AM
- Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRNA • PR Newswire (US) • 09/12/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:27 PM
- Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases • PR Newswire (US) • 09/10/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/09/2024 07:29:35 PM
- Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 09/09/2024 02:26:00 PM
- Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/05/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:42:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:26:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:58:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:42:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:37:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:34:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:32:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:03:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:52:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:43:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:38:25 PM
- Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 08/29/2024 09:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:47:40 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM